Elunate Use In Pregnancy & Lactation

Contraception: Women of childbearing age must be informed that this product may cause harm to fetus. Women of childbearing age are required to undergo a pregnancy test to rule out the possibility of pregnancy before taking this product.
Women of childbearing age should take effective contraceptive measures during the treatment period and up to 1 month after treatment.
Male patients should take effective contraceptive measures during the treatment period and up to 1 month after treatment.
Pregnancy: At present, there is still no clinical study about the effects of this product on pregnant women. Based on its mechanism of action, this product may cause harm to the fetus if a pregnant woman takes this product. In a developmental toxicity study in rats, it was observed that fruquintinib has teratogenicity, embryotoxicity and fetotoxicity when the maternal exposure is lower than the human exposure based on recommended clinical dose. Hence, the use of this product is prohibited during pregnancy.
Breastfeeding: At present, it is still unclear whether this product is excreted through human breast milk. As most of the drugs are excreted through breast milk, the risk of this product to nursing infants cannot be ruled out. Breastfeeding must be discontinued during the treatment with this product.
Fertility: At present, there is no data on the effects of this product on human fertility. Results from animal studies showed that fruquintinib may damage the fertility of male and female animals (refer to Pharmacology: Toxicology under Actions).